Matthew T. Roe

Matthew T. Roe

Auto-generated profile, based on publicly available information

Matthew T. Roe

Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MRMatthew T. Roe
Matthew T. Roe
PAPaul W. Armstrong
Paul W. Armstrong
KFKeith A.A. Fox
Keith A.A. Fox
HWHarvey D. White
Harvey D. White
DPDorairaj Prabhakaran
Dorairaj Prabhakaran
EOE. Magnus Ohman
E. Magnus Ohman
The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.)

7 November 2012 in JAMA
Verified
Journal Article
Open access
PDF file
PGPaul A. Gurbel
Paul A. Gurbel
DEDavid Erlinge
David Erlinge
EOE. Magnus Ohman
E. Magnus Ohman
BNBenjamin Neely
Benjamin Neely
MNMegan Neely
Megan Neely
MRMatthew T. Roe
Matthew T. Roe
Platelet-rich thrombus formation plays a major role in the occurrence of ischemic events in patients with acute coronary syndromes (ACS).1 A large body of evidence, primarily based on single ex vivo measurements, demonstrates an association between high on-treatment platelet reactivity to adenosine diphosphate and the occurrence of ischemic events among patients treated with clopidogrel following percutaneous coronary intervention (PCI); however, many questions regarding this association remain unanswered.2-4

5 September 2000 in Circulation
Verified
Journal Article
Closed access
MRMatthew T. Roe
Matthew T. Roe
RHRobert A. Harrington
Robert A. Harrington
DPDanielle M. Prosper
Danielle M. Prosper
KPKaren S. Pieper
Karen S. Pieper
DBDeepak L. Bhatt
Deepak L. Bhatt
ETEric J. Topol
Eric J. Topol
Background —A proportion of patients who present with suspected acute coronary syndrome (ACS) are found to have insignificant coronary artery disease (CAD) during coronary angiography, but these patients have not been well characterized. Methods and Results —Of the 5767 patients with non–ST-segment elevation ACS who were enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and who underwent in-hospital angiography, 88% had significant CAD (any stenosis >50%), 6% had mild CAD (any stenosis >0% to ≤50%), and 6% had no CAD (no stenosis identified). The frequency of death or nonfatal myocardial infarction at 30 days was reduced with eptifibatide treatment in patients with significant CAD (18.3% versus 15.6% for placebo, P =0.006) but not in those with mild CAD (6.6% versus 5.4%, P =0.62) and with no CAD (3.0% versus 1.2%, P =0.28). We identified independent baseline predictors of insignificant CAD (mild or no CAD) and used them to develop a simple predictive nomogram of the probability of insignificant CAD for use at hospital presentation. This nomogram was validated in a separate population of patients with non–ST-segment elevation ACS. Conclusions —Patients with suspected ACS found to have insignificant CAD have a low risk of adverse outcomes, do not appear to benefit from treatment with eptifibatide, and can be predicted with a simple nomogram drawn from baseline characteristics. Because patients with significant CAD appear to have an enhanced benefit from eptifibatide treatment, the predictive nomogram developed can be used to determine indications for glycoprotein IIb/IIIa blockade.

1 April 2020 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
ANAdam J. Nelson
Adam J. Nelson
PRPaolo Raggi
Paolo Raggi
MWMyles Wolf
Myles Wolf
AGAlexander M. Gold
Alexander M. Gold
GCGlenn M. Chertow
Glenn M. Chertow
MRMatthew T. Roe
Matthew T. Roe
Cardiovascular (CV) disease remains an important cause of morbidity and mortality for patients with chronic kidney disease (CKD). Although clustering of traditional risk factors with CKD is well recognized, kidney-specific mechanisms are believed to drive the disproportionate burden of CV disease. One perturbation that is frequently observed at high rates in patients with CKD is vascular calcification, which may be a central mediator for an array of CV sequelae. This review summarizes the pathophysiological bases of intimal and medial vascular calcification in CKD, current strategies for diagnosis and management, and posits vascular calcification as a risk marker and therapeutic target.

20 August 2013 in Circulation
Verified
Journal Article
Closed access
MRMatthew T. Roe
Matthew T. Roe
SGShaun G. Goodman
Shaun G. Goodman
EOE. Magnus Ohman
E. Magnus Ohman
SSSusanna R. Stevens
Susanna R. Stevens
JHJudith S. Hochman
Judith S. Hochman
PAPaul W. Armstrong
Paul W. Armstrong
Background—: Dual antiplatelet therapy in older versus younger patients with acute coronary syndromes is understudied. Low-dose prasugrel (5 mg/d) is recommended for younger, lower-body-weight patients and elderly patients with acute coronary syndromes to mitigate the bleeding risk of standard-dose prasugrel (10 mg/d). Methods and Results—: A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months. A total of 515 participants ≥75 years of age (25% of total elderly population) had serial platelet reactivity unit measurements in a platelet-function substudy. Cumulative risks of the primary end point (cardiovascular death/myocardial infarction/stroke) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding increased progressively with age and were ≥2-fold higher in older participants. Among those ≥75 years of age, TIMI major bleeding (4.1% versus 3.4%; hazard ratio, 1.09; 95% confidence interval, 0.57–2.08) and the primary end point rates were similar with reduced-dose prasugrel and clopidogrel. Despite a correlation between lower 30-day on-treatment platelet reactivity unit values and lower weight only in the prasugrel group, there was a nonsignificant treatment-by-weight interaction for platelet reactivity unit values among participants ≥75 years of age in the platelet-function substudy ( P =0.06). No differences in weight were seen in all participants ≥75 years of age with versus without TIMI major/minor bleeding in both treatment groups. Conclusions—: Older age is associated with substantially increased long-term cardiovascular risk and bleeding among patients with medically managed acute coronary syndromes, with no differences in ischemic or bleeding outcomes with reduced-dose prasugrel compared with clopidogrel in elderly patients. No significant interactions among weight, pharmacodynamic response, and bleeding risk were observed between reduced-dose prasugrel and clopidogrel in elderly patients. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov/ct2/home . Unique identifier: NCT0069999.

1 June 2006 in American Heart Journal
Verified
Journal Article
Closed access
MRMatthew T. Roe
Matthew T. Roe
EPEric D. Peterson
Eric D. Peterson
LNL. Kristin Newby
L. Kristin Newby
ACAnita Y. Chen
Anita Y. Chen
CPCharles V. Pollack
Charles V. Pollack
EOE. Magnus Ohman
E. Magnus Ohman